New agents for chemoprevention of prostate cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 10325499.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The magnitude of the problem of prostate cancer, and the failure of conventional chemotherapy and surgery to effect a marked diminution in the total number of deaths from this disease, now indicate that chemoprevention of prostatic carcinogenesis must be seriously considered. We describe the development of a new system for quantitating the process of prostatic carcinogenesis in an experimental animal, and the use of this system to demonstrate that the retinoid, 4-hydroxyphenylretinamide, the deltanoid, Ro24-5531, and the estrogen analog, tamoxifen, all are effective agents for prevention of experimental prostate cancer.
Medical subject headings
- Anticarcinogenic Agents
- Calcitriol
- Drugs, Investigational
- Fenretinide
- Prostatic Neoplasms
- Tamoxifen